Welcome to our dedicated page for Aspire Biopharma Holdings SEC filings (Ticker: ASBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspire Biopharma Holdings, Inc. filings document capital-structure actions, shareholder voting matters, and material agreements tied to its public securities. Proxy statements and current reports cover warrant share authorizations, warrant exercise-price and share adjustments, Series A Convertible Preferred Stock financing, registration rights, conversion-share approvals under Nasdaq Rule 5635(d), and reverse-split authority.
The filing record also includes amended material-event reports and stockholder meeting disclosures. These documents describe governance procedures, security-holder approvals, public-company compliance matters, operating and financial reporting categories, and formal disclosure related to the company’s drug-delivery business and security structure.
The filing is a Definitive Proxy Statement for Aspire Biopharma Holdings, Inc. (ticker ASBPW) and includes shareholder voting materials and ownership details. The extract lists several named holders with specific share counts and ownership percentages, including Kraig T. Higginson at 10,531,193 shares representing 21.6% and a group or aggregate entry showing 12,797,468 shares or 25.8%. Other disclosed holdings include Surendra Ajjarapu with 1,121,736 shares (2.3%), Ernest J. Scheidemann, Jr. with 564,168 shares (1.1%), and smaller positions for Edward J. Kimball, Howard Doss, and Donald G. Fell (share counts shown; percentages marked with * in the extract). The document also includes standard proxy checkboxes and a company address in Estero, Florida, plus a reference to the Certificate of Incorporation. The content is a fragmentary excerpt focused on ownership and proxy logistics rather than financial results.
Aspire Biopharma Holdings, Inc. (ASBPW) S-1 describes the company’s IPO-related capital structure, Trust Account holdings, related-party financing and post-transaction balances following its business combination activity. The company completed a Unit offering that funded a Trust Account (approximately $294.7 million initially) and recorded redemptions that reduced Trust Account balances to $6.67 million at December 31, 2024 and thereafter to amounts described as held for a Business Combination. The filing discloses substantial subscription agreement loans, working capital loans, multiple original-issue-discount (OID) notes to related parties, and convertible/debt instruments with debt discounts and fair-value adjustments recorded as large non-cash charges. Management reports a working capital deficit and notes substantial doubt about the company’s ability to continue as a going concern without additional financing. The record shows issuance and conversion of multiple share classes, sponsor/affiliate commitments, warrant pools outstanding, and material related-party transactions and contingent fees tied to the Business Combination.